R27.0 G11
Conditions
Interventions
Group 1: Up to 30 SCA1, 2, 3 or 6 mutation carriers and their first-degree relatives and 20 healthy controls will be included. The examination as part of the study takes around 120 minutes, 60 minutes
Sponsors
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Written informed consent - Fulfilment of the inclusion criteria of the defined diagnostic group, in this case mutation carriers for SCA1, 2, 3 or 6 as well as their first-degree relatives or healthy controls.
Exclusion criteria
Exclusion criteria: - Lack of capacity to give consent. - Contraindications against MRI examinations - Clinical instability or malignant underlying disease - Simultaneous participation in an intervention study with an investigational drug for the treatment of spinocerebellar ataxia (SCA)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim is to establish quantitative UHF-MRI biomarkers for polyglutamine SCAs that have a high potential for the detection of early structural disease manifestations and are suitable for mapping disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Back-translation of the UHF MRI sequences assessed as sensitive to the lower field strength of 3T. | — |
Countries
Belgium, Germany, Norway
Contacts
Public ContactJennifer Faber
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn
Outcome results
None listed